Over-the-Counter availability— Notwithstanding any other provision of law, with respect to individuals under age 18, a contraceptive drug that is eligible for priority review under subsection (a) shall be subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act (
21 U.S.C. 353(b)(1)), including after approval of the supplemental application as described in subsection (a)(2).